Last reviewed · How we verify
NCT04374617
Risk of Venous Thromboembolism in Critically Ill Patients With Severe COVID-19
trial testing Duplex ultrasound and Computed Tomography Angiography in COVID-19 in 230 participants. Completed in 1 May 2020.
25 April 2020
Quick facts
| Lead sponsor | Hospital Universitari Vall d'Hebron Research Institute |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 230 |
| Start date | 1 April 2020 |
| Primary completion | 25 April 2020 |
| Estimated completion | 1 May 2020 |
| Sites | 3 locations across Spain |
Drugs / interventions tested
- Duplex ultrasound and Computed Tomography Angiography
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- Critical Illness — all drugs for Critical Illness →
- Venous Thromboembolism — all drugs for Venous Thromboembolism →
- Venous Thromboses — all drugs for Venous Thromboses →
Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Who can join
18 and older, any sex, with COVID-19 or Critical Illness. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Severe COVID-19 patients at a high risk of venous thromboembolism. We studied patients in 2 intensive care units of university hospitals in Barcelona and Badalona, Spain. We performed a cut-off screening of deep venous thrombosis (DVT) with bilateral duplex ultrasound to 230 patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04374617
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Hospital Universitari Vall d'Hebron Research Institute trials
Trials by the same sponsor.
- NCT07519343 — Migraine and Endometriosis: The FEMININE Study · not yet recruiting
- NCT07509541 — Hemodynamic and Respiratory Instability During Percutaneous Pulmonary Thrombectomy · not yet recruiting
- NCT07456280 — Evaluation of the Non-invasive Electrocardiographic Monitoring Strategy Associated With Early Discharge in Patients With · NA · not yet recruiting
- NCT07281911 — Early Biological and Mechanical Profiling in Sepsis-Associated ARDS · not yet recruiting
- NCT07430501 — Using Digital Twin Technology and Clinical Decision Support Systems to Improve the Early Detection, Personalised Treatme · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04374617 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Universitari Vall d'Hebron Research Institute
- Last refreshed: 6 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04374617.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing